Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. April 11, 2022

 Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 10.30 a.m. and concluded at 12:45 p.m. inter- alia have considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and financial Year ended March 31, 2022. 2. Recommendation of the final Dividend of Rs 0.25 (2.5%) per equity share for the financial year ended March 31, 2022, subject to the approval of the shareholders at the ensuing General Meeting of the Company.
11-04-2022
Bigul

Annual report for Lasa Supergenerics Ltd. for FY-2022
11-04-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ankita ShettyDesignation :- Company Secretary and Compliance Officer
08-04-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Clarification On Significant Price Movement

 This is with reference to communication received from NSE vide email dated April 06, 2022 Ref No.NSE/CM/Surveillance seeking clarification in significant price moment and clarification sought by BSE vide update on corporate announcement section on website for significant movement in the price of the shares of the Company across exchanges. In this regard, we wish to inform you that the Company is in compliance with SEBI (LODR) Regulations, 2015 and has been promptly informing the Stock Exchange on all events and information, which have a bearing on operation or performance of the Company. The upcoming Board meeting which is scheduled to be held on Monday April 11 ,2022 where the Board of Directors may consider the dividend which is disclosed in intimation dated March 21,2022 might be the reason for the price movement.
07-04-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Clarification sought from Lasa Supergenerics Ltd

 The Exchange has sought clarification from Lasa Supergenerics Ltd on April 6, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
06-04-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Period Ended March 31, 2022

 This is to certify that in compliance with regulation 7(2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, all activities in relation to share transfer facility are maintained by our Share Transfer Agent i.e. Bigshare Services Private Limited having permanent SEBI Registration No INR0000001385. This certificate for the year ended 31st March 2022 is issued in compliance with Regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
05-04-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Closure of Trading Window

 In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct, the Trading Window shall continue to remain closed from March 21, 2022 till 48 hours after the declaration of the Audited financial results of the Company for the quarter and year ended March 31, 2022.
21-03-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for Consideration Of Audited Financials And To Consider And Recommend Dividend For The Financial Year Ended March 31, 2022, Subject To The Approval Of The Shareholders At The Ensuing General Meeting Of The Company.

 Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/04/2022 ,inter alia, to consider and approve 1. To consider, approve and take on records Audited financial results of the Company for the quarter and year ended March 31, 2022. 2. To consider and recommend the dividend for the financial year ended March 31, 2022, subject to the approval of the shareholders at the ensuing General Meeting of the Company. 3. To discuss any other matter with the permission of the Chairperson.
21-03-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 15, 2022 for Omkar Pravin Herlekar
15-02-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. February 07, 2022

 Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which commenced at 02.00 p.m. and concluded at 3.30 p.m. inter- alia has considered and approved the following: 1. The statement of un-audited financial result for the quarter and nine months ended December 31, 2021. 2. Limited review Report from Statutory Auditor for the quarter ended December 31, 2021.
07-02-2022
Next Page
Close

Let's Open Free Demat Account